• About
    Mission and HistoryExpertsIndependence and TransparencyInternships/Research Fellows
  • Explore Our WorkExplore Our Work
    • Our Work
      • Work
        • Amicus Briefs
        • Diversity and Inclusion
        • Economic & Policy Analysis
        • Fair Fight Film
        • Grant Research
        • Legal Analysis
        • Podcasts
        • Public Comments and Testimony
        • Reports
      • Issues By Sector
        • Airlines
        • Banking & Finance
        • Digital Technology
        • Energy
        • Food & Agriculture
        • Health & Pharmaceuticals
        • Innovation & Entrepreneurship
        • Intellectual Property
        • International
        • Labor
        • Media & Communications
        • Retail & Distribution
        • Transportation
      • Issues By Enforcement Area
        • Buyer Power
        • Cartels
        • Collusion
        • Exemptions & Immunities
        • Mergers
        • Monopolies
        • Private Enforcement
        • Public Enforcement
  • Events
  • Awards
    Alfred E. Kahn Award for Antitrust AchievementAntitrust Enforcement AwardsPrivate Antitrust Enforcement Hall of FameHollis Salzman Memorial Leadership AwardJerry S. Cohen Award for Antitrust Scholarship (administered by Cohen Milstein and hosted by AAI)
  • CLE Programs
  • Support
    Supporting AAIDonateSponsorshipsCy PresGrants
In The News

AAI’s Perspective on Acquisitions Reported Under the HSR Act Noted in JDSupra

February 19, 2020
Technology , Monopolies , FTC , Competition Policy

JDSupra’s February 19 posting by Morrison & Foerster LLP “FTC Uses ‘Study Authority’ To Review Prior Non-HSR Reportable Tech Transactions” cited AAI’s white paper “The Record of Weak U.S. Merger Enforcement in Big Tech” by AAI President Diana Moss from July 9, 2019.

Related Work

In The News

Stutz Discusses FTC Rulemaking and Legislation at the National Press Club

June 28, 2022 | Randy Stutz
FTC , Legislation
Amicus Briefs

AAI Asks Second Circuit for Clear Thinking When Pharmaceutical Markets Are Monopolized by Patent Fraud (Regeneron v. Novartis)

June 20, 2022 | Randy Stutz
Exclusionary Conduct , Intellectual Property , Monopolies , Health & Pharmaceuticals
In The News

FTC Commissioners Cite AAI Study on Private Equity in Healthcare in Support of Merger Action

June 16, 2022
Competition Policy , FTC , Health & Pharmaceuticals , Mergers , Private Equity , Section 7 of the Clayton Act
Reports

AAI Report Examines FTC’s Pharmaceutical Merger Policy in Light of Mounting Antitrust Violations, Calls for Overhaul of Commission’s Approach of Approving Mergers Subject to Divestitures

June 14, 2022 | Diana L. Moss
Health & Pharmaceuticals , FTC , Mergers

Support AAI

Promoting competition that protects consumers, businesses, and society is more important than ever. Through our research, education, and advocacy programs, AAI has been active in focusing public and private competition enforcement priorities and shaping progressive competition policy. The only way for AAI to fulfill its mission is through your support.

Learn More

Address

1025 Connecticut Avenue, NW
Suite 1000
Washington, DC 20036
(202) 828-1226

Join Our Mailing List

    • About
    • Terms of Use
    • Contact Us
    • Support

    Copyright © American Antitrust Institute 2022